Activity of ampicillin-sulbactam and oxacillin in experimental endocarditis caused by beta-lactamase-hyperproducing Staphylococcus aureus.

Antimicrobial Agents and Chemotherapy
A PefanisR C Moellering

Abstract

Using a rat model of aortic valve infective endocarditis, we previously found that oxacillin was equally effective against an oxacillin-susceptible strain of Staphylococcus aureus and a beta-lactamase-hyperproducing borderline oxacillin-susceptible strain of S. aureus; also, ampicillin-sulbactam was less effective than oxacillin against both isolates and at low doses was less effective against the borderline-susceptible strain than against the fully oxacillin-susceptible strain (C. Thauvin-Eliopoulos, L. B. Rice, G. M. Eliopoulos, and R. C. Moellering, Jr., Antimicrob. Agents Chemother. 34:728-732, 1990). In the present study, we extended this work, using alternative treatment schedules and additional bacterial strains. Extending treatment with low doses of ampicillin-sulbactam (500 and 250 mg/kg of body weight per day, respectively) to 6.5 days resulted in equalization of effectiveness against the previously studied strains BOSSA-1 and OSSA-1 (3.75 +/- 1.61 log10 and 4.71 +/- 1.79 log10 CFU of residual viable bacteria per g, respectively). Against the borderline oxacillin-susceptible strain BOSSA-1, increasing the sulbactam dosage from 500 to 2,000 mg/kg/day while maintaining a fixed dose of ampicillin (1,000 mg/kg/day) by con...Continue Reading

References

Mar 1, 1978·Infection and Immunity·J Santoro, M E Levison
Jul 1, 1992·Journal of Clinical Microbiology·S UnalP L Skatrud
Apr 1, 1989·Antimicrobial Agents and Chemotherapy·H F ChambersM Matsuhashi
Feb 1, 1987·Antimicrobial Agents and Chemotherapy·C ThauvinR C Moellering
Dec 5, 1985·The New England Journal of Medicine·K Godfrey
Apr 1, 1972·Antimicrobial Agents and Chemotherapy·C H O'CallaghanA H Shingler

❮ Previous
Next ❯

Citations

Mar 1, 1995·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·O HammerbergR Behme
May 1, 1994·Diagnostic Microbiology and Infectious Disease·G ZambardiJ Fleurette
Jul 2, 2003·Drugs·Nelson LeeCyrus R Kumana
Jun 4, 2015·Annual Review of Biochemistry·Sharon J Peacock, Gavin K Paterson
Oct 1, 2010·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S CroesE E Stobberingh
Jul 17, 2021·Journal of Medical Microbiology·Maria M KonstantinovskiJairo Gooskens

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

© 2021 Meta ULC. All rights reserved